Time filter

Source Type

Moriconi A.,Dompe Pha.r.ma S.p.a. | Cerbara I.,Colosseum Combinatorial Chemistry Center For Technology a Rl | Maccarrone M.,University of Teramo | Maccarrone M.,European Center for Brain Research | And 2 more authors.
Current Medicinal Chemistry | Year: 2010

In the last decade, accumulated evidence highlighted that GPR55 might be activated by several classical cannabinoid ligands, making this orphan receptor the main candidate to be considered as the "third" cannabinoid receptor. The investigation of its pharmacology has often provided divergent and more intricate results, that have complicated the understanding of the physiological role of GPR55. Nevertheless, the patent analysis regarding GPR55 outlines the fair interest of big pharmaceutical companies, especially in the first years of this decade. This investigation provides a brief overview of the current "state of the art" of our knowledge of GPR55, giving particular emphasis to its functional selectivity. This property could account for controversial roles of GPR55, whose pharmacology and downstream signaling is known to vary significantly both in ligand- and system-dependent manners. In addition, we gain insights into the challenging aspect of finding out novel GPR55 modulators, by analyzing conserved structural and functional motifs that, together with future studies, could help to elucidate its mechanism of action and to design more selective and potent small-molecules directed towards GPR55. Preliminary data highlight remarkable differences, but also intriguing commonalities, between GPR55 and other members of class A G-protein-coupled receptors. It is anticipated that, in the next future, novel lead candidates targeting GPR55 could represent new tools to better understand GPR55-mediated human diseases and, hopefully, generate an innovative class of effective next-generation therapeutics. © 2010 Bentham Science Publishers Ltd.

Topai A.,Colosseum Combinatorial Chemistry Center For Technology a Rl | Breccia P.,Chesterford Research Park | Minissi F.,Colosseum Combinatorial Chemistry Center For Technology a Rl | Padova A.,Siena Biotech S.p.A. | And 2 more authors.
Bioorganic and Medicinal Chemistry | Year: 2012

Among matrix metalloproteinases (MMPs), gelatinases MMP-2 (gelatinase A) and MMP-9 (gelatinase B) play a key role in a number of physiological processes such as tissue repair and fibrosis. Many evidences point out their involvement in a series of pathological events, such as arthritis, multiple sclerosis, cardiovascular diseases, inflammatory processes and tumor progression by degradation of the extracellular matrix. To date, the identification of non-specific MMP inhibitors has made difficult the selective targeting of gelatinases. In this work we report the identification, design and synthesis of new gelatinase inhibitors with appropriate drug-like properties and good profile in terms of affinity and selectivity. By a detailed in silico protocol and innovative and versatile solid phase approaches, a series of 4-thiazolydinyl-N-hydroxycarboxyamide derivatives were identified. In particular, compounds 9a and 10a showed a potent inhibitory activity against gelatinase B and good selectivity over the other MMP considered in this study. The identified compounds could represent novel potential candidates as therapeutic agents. © 2012 Elsevier Ltd. All rights reserved.

Loading Colosseum Combinatorial Chemistry Center For Technology a Rl collaborators
Loading Colosseum Combinatorial Chemistry Center For Technology a Rl collaborators